Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Phase 3
Completed
NCT04527991
| Condition | Locally Advanced or Metastatic Unresectable Urothelial Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Gilead Sciences |
|---|
| Status | Completed |
|---|
| Enrollment | 711 participants |
|---|
| Interventions | Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel, Vinflunine |
|---|
| Start date | Jan 13, 2021 |
|---|
| Completion date | Jul 4, 2025 |
|---|
| Results posted | Jun 2, 2026 |
|---|
Summary
The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).
Overall Survival (OS)
Up to 42 months · months
| Sacituzumab Govitecan-hziy (SG) | 10.3 months |
|---|
| Treatment of Physician's Choice | 9.0 months |
|---|
| p-value | 0.0870 |
|---|
| Stratified Hazard Ratio | 0.86 (95% CI 0.73–1.02) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.